Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Annual meeting

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 12, 2021 12:53pm

81 Views

Post# 32977962

RE:RE:RE:RE:RE:RE:Annual meeting

"QWERTY says the FDA will not reverse its decision on the phase III trial but I have to think that fear of a reversal might be playing a role in this situation."

I would never say "will not" when it comes to regulators but...... From what we understand they aren't presenting new data in these continuing discussions so I don't understand how the FDA can reverse their clinical decision. On what basis would they do that?

SPCEO1 wrote: Unless we are missing something the analysts can see, there is just no excuse for the company not being able to convince the market that NASH is real and therefore the stock deserves to be valued like all the other late stage NASH stocks.

I mean, it really should not be hard to convince investors if you have been able to convince the FDA.

QWERTY says the FDA will not reverse its decision on the phase III trial but I have to think that fear of a reversal might be playing a role in this situation. The Biden FDA has already shown itself to be less friendly to companies than the Trump FDA. Still, the bigger problem is likely the fact that most investors are unaware of the situation. If insitutional investors are not listening to the TH messengers on this, than maybe Paul needs to get more aggressive himself in speaking to those investors.

scarlet1967 wrote:
Many have said it before the valuation is the projection of the market's perception so the market didn't ascribe any value to phase 3 NASH even with FDA's go a head meaning market doesn't believe in their program at all despite the fact that the agency does.
Now we know their approach is different which is the possible reason why the market doesn't understand it, they managed to convince the agency now they have to convince the market and that's where it all falls apart. The market equaled difference as no value so the company has to change that perception...

Bucknelly21 wrote: I'm curious does getting the fda letter to proceed for phase 3 and the market not even sniffing at it the same kind of irrational market behavior you are referring too?